• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受强力霉素治疗的登革热患者死亡率较低,这与白细胞介素-6和肿瘤坏死因子水平降低有关。

Dengue Patients Treated with Doxycycline Showed Lower Mortality Associated to a Reduction in IL-6 and TNF Levels.

作者信息

Fredeking Terry M, Zavala-Castro Jorge E, González-Martínez Pedro, Moguel-Rodríguez William, Sanchez Ernesto C, Foster Michael J, Diaz-Quijano Fredi A

机构信息

Departamento de Epidemiologia, Faculdade de Saude Publica da Universidade de Sao Paulo, Av. Dr. Arnaldo, 715, Cerqueira Cesar, CEP 01246-904, Sao Paulo, SP, Brazil.

出版信息

Recent Pat Antiinfect Drug Discov. 2015;10(1):51-8. doi: 10.2174/1574891x10666150410153839.

DOI:10.2174/1574891x10666150410153839
PMID:25858261
Abstract

OBJECTIVE

To determine the effect of doxycycline treatment on cytokine levels, including tumor necrosis factor (TNF) and interleukin 6 (IL-6), and mortality in dengue patients at high risk of complication.

METHODS

A group of dengue hemorrhagic fever patients (n=231) were randomized to receive either standard supportive care or supportive care in addition to oral doxycycline twice daily for 7 days. Dengue virus infection was confirmed by PCR using multiple primers. Serum samples were obtained at days 0, 3, 5 and 7 and tested for levels of TNF and IL-6.

RESULTS

Doxycycline-treated group presented a 46% lower mortality than that observed in the untreated group (11.2% [13/116] vs 20.9% [24/115], respectively, p=0.05). Moreover, administration of doxycycline resulted in a significant (p<0.01) decrease in levels of TNF and IL-6 versus controls in the tests performed during follow-up (day 3, 5 and 7). Patients who died in both groups possessed significantly (p<0.01) higher levels of TNF and IL-6 compared to those who survived at all-time points.

CONCLUSION

The above findings suggest that doxycycline can provide a clinical benefit to dengue patients at high risk of complications. This effect could be mediated by decreasing pro-inflammatory cytokine levels.

摘要

目的

确定强力霉素治疗对细胞因子水平(包括肿瘤坏死因子(TNF)和白细胞介素6(IL-6))的影响,以及对有并发症高风险的登革热患者死亡率的影响。

方法

一组登革出血热患者(n = 231)被随机分为两组,一组接受标准支持治疗,另一组除标准支持治疗外,每天口服两次强力霉素,持续7天。使用多种引物通过PCR确认登革病毒感染。在第0、3、5和7天采集血清样本,检测TNF和IL-6水平。

结果

强力霉素治疗组的死亡率比未治疗组低46%(分别为11.2% [13/116] 和20.9% [24/115],p = 0.05)。此外,在随访期间(第3、5和7天)进行的测试中,与对照组相比,强力霉素的使用导致TNF和IL-6水平显著降低(p < 0.01)。与在所有时间点存活的患者相比,两组中死亡的患者TNF和IL-6水平均显著更高(p < 0.01)。

结论

上述研究结果表明,强力霉素可为有并发症高风险的登革热患者带来临床益处。这种效果可能是通过降低促炎细胞因子水平来介导的。

相似文献

1
Dengue Patients Treated with Doxycycline Showed Lower Mortality Associated to a Reduction in IL-6 and TNF Levels.接受强力霉素治疗的登革热患者死亡率较低,这与白细胞介素-6和肿瘤坏死因子水平降低有关。
Recent Pat Antiinfect Drug Discov. 2015;10(1):51-8. doi: 10.2174/1574891x10666150410153839.
2
Modulation of cytokine and cytokine receptor/antagonist by treatment with doxycycline and tetracycline in patients with dengue fever.多西环素和四环素治疗登革热患者对细胞因子及细胞因子受体/拮抗剂的调节作用
Clin Dev Immunol. 2011;2011:370872. doi: 10.1155/2011/370872. Epub 2011 Mar 28.
3
Primary dengue virus infections induce differential cytokine production in Mexican patients.原发性登革病毒感染在墨西哥患者中诱导不同的细胞因子产生。
Mem Inst Oswaldo Cruz. 2016 Mar;111(3):161-7. doi: 10.1590/0074-02760150359.
4
Serum levels of interleukin-6, tumor necrosis factor-alpha and interferon-gamma in infants with and without dengue.患登革热和未患登革热婴儿的血清白细胞介素-6、肿瘤坏死因子-α和干扰素-γ水平
Rev Soc Bras Med Trop. 2008 Jan-Feb;41(1):6-10. doi: 10.1590/s0037-86822008000100002.
5
Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial.铁蛋白水平、炎症生物标志物与外周动脉疾病患者的死亡率:铁(Fe)与动脉粥样硬化研究(FeAST)试验的子研究。
J Vasc Surg. 2010 Jun;51(6):1498-503. doi: 10.1016/j.jvs.2009.12.068. Epub 2010 Mar 20.
6
Cytokine profiles in dengue fever and dengue hemorrhagic fever: A study from Indonesia.登革热和登革出血热的细胞因子谱:来自印度尼西亚的一项研究。
Narra J. 2024 Apr;4(1):e309. doi: 10.52225/narra.v4i1.309. Epub 2024 Mar 8.
7
Inflammatory Markers and Outcomes in Kidney Transplant Recipients.肾移植受者的炎症标志物与预后
Transplantation. 2017 Sep;101(9):2152-2164. doi: 10.1097/TP.0000000000001548.
8
Slow resolution of inflammation in severe adult dengue patients.重症成年登革热患者炎症消退缓慢。
BMC Infect Dis. 2016 Jun 14;16:291. doi: 10.1186/s12879-016-1596-x.
9
Genetic Polymorphisms of Tumor Necrosis Factor Alpha and Susceptibility to Dengue Virus Infection in a Mexican Population.肿瘤坏死因子α基因多态性与墨西哥人群登革病毒感染易感性
Viral Immunol. 2017 Oct;30(8):615-621. doi: 10.1089/vim.2017.0029. Epub 2017 Jun 26.
10
Efficacy of zinc supplementation on serum calprotectin, inflammatory cytokines and outcome in neonatal sepsis - a randomized controlled trial.补充锌对新生儿败血症血清钙卫蛋白、炎性细胞因子及预后的影响——一项随机对照试验
J Matern Fetal Neonatal Med. 2017 Jul;30(13):1627-1631. doi: 10.1080/14767058.2016.1220524. Epub 2016 Aug 25.

引用本文的文献

1
Novel and repurposed antiviral molecules for arbovirus infections with epidemic Potential: A systematic review.用于具有流行潜力的虫媒病毒感染的新型及重新利用的抗病毒分子:一项系统综述。
New Microbes New Infect. 2025 Jul 10;66:101614. doi: 10.1016/j.nmni.2025.101614. eCollection 2025 Aug.
2
A lethal DENV-2 wild-type mouse model for mutagenesis investigations.用于诱变研究的致死性登革热病毒2型野生型小鼠模型。
BMC Biol. 2025 Jul 21;23(1):218. doi: 10.1186/s12915-025-02332-6.
3
In Silico Evaluation of Potential Hit Molecules Against Multiple Serotypes of Dengue Virus Envelope Glycoprotein.
针对登革病毒包膜糖蛋白多种血清型的潜在活性分子的计算机模拟评估
Molecules. 2025 Mar 12;30(6):1268. doi: 10.3390/molecules30061268.
4
Repurposing doxycycline for Alzheimer's treatment: Challenges from a nano-based drug delivery perspective.将强力霉素重新用于治疗阿尔茨海默病:基于纳米药物递送视角的挑战
Brain Behav Immun Health. 2024 Oct 25;42:100894. doi: 10.1016/j.bbih.2024.100894. eCollection 2024 Dec.
5
Repositioning of Antibiotics in the Treatment of Viral Infections.抗生素在病毒感染治疗中的再定位。
Curr Microbiol. 2024 Oct 26;81(12):427. doi: 10.1007/s00284-024-03948-7.
6
Structure-based identification of small-molecule inhibitors that target the DIII domain of the Dengue virus glycoprotein E pan-serotypically.基于结构的泛血清型登革病毒糖蛋白 E 结构域小分子抑制剂的鉴定。
PLoS One. 2024 Oct 25;19(10):e0311548. doi: 10.1371/journal.pone.0311548. eCollection 2024.
7
Orthoflaviviral Inhibitors in Clinical Trials, Preclinical In Vivo Efficacy Targeting NS2B-NS3 and Cellular Antiviral Activity via Competitive Protease Inhibition.在临床试验中靶向 NS2B-NS3 的正交黄病毒抑制剂,通过竞争性蛋白酶抑制的临床前体内疗效和细胞抗病毒活性。
Molecules. 2024 Aug 27;29(17):4047. doi: 10.3390/molecules29174047.
8
Targeting the host response in sepsis: current approaches and future evidence.靶向脓毒症的宿主反应:当前方法和未来证据。
Crit Care. 2023 Dec 6;27(1):478. doi: 10.1186/s13054-023-04762-6.
9
Possible therapeutic targets for SARS-CoV-2 infection and COVID-19.新型冠状病毒(SARS-CoV-2)感染及新冠肺炎(COVID-19)可能的治疗靶点。
J Allergy Infect Dis. 2021;2(3):75-83. doi: 10.46439/allergy.2.028.
10
Potential Drugs in COVID-19 Management.新冠病毒管理中的潜在药物。
Curr Med Chem. 2024;31(22):3245-3264. doi: 10.2174/0929867331666230717154101.